Uma Malhotra

Dr. Uma Malhotra

University of Washington/ Virginia Mason Medical Center
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
OKOlivia S Kates
Olivia S Kates
BHBrandy M Haydel
Brandy M Haydel
SFSander S Florman
Sander S Florman
MRMeenakshi M Rana
Meenakshi M Rana
ZCZohra S Chaudhry
Zohra S Chaudhry
ZLZurabi Lominadze
Zurabi Lominadze
Background: The coronavirus disease 2019 (COVID-19) pandemic has led to significant reductions in transplantation, motivated in part by concerns of disproportionately more severe disease among solid organ transplant (SOT) recipients. However, clinical features, outcomes, and predictors of mortality in SOT recipients are not well described. Methods: We performed a multicenter cohort study of SOT recipients with laboratory-confirmed COVID-19. Data were collected using standardized intake and 28-day follow-up electronic case report forms. Multivariable logistic regression was used to identify risk factors for the primary endpoint, 28-day mortality, among hospitalized patients. Results: Four hundred eighty-two SOT recipients from >50 transplant centers were included: 318 (66%) kidney or kidney/pancreas, 73 (15.1%) liver, 57 (11.8%) heart, and 30 (6.2%) lung. Median age was 58 (interquartile range [IQR] 46–57), median time post-transplant was 5 years (IQR 2–10), 61% were male, and 92% had ≥1 underlying comorbidity. Among those hospitalized (376 [78%]), 117 (31%) required mechanical ventilation, and 77 (20.5%) died by 28 days after diagnosis. Specific underlying comorbidities (age >65 [adjusted odds ratio [aOR] 3.0, 95% confidence interval [CI] 1.7–5.5, P < .001], congestive heart failure [aOR 3.2, 95% CI 1.4–7.0, P = .004], chronic lung disease [aOR 2.5, 95% CI 1.2–5.2, P = .018], obesity [aOR 1.9, 95% CI 1.0–3.4, P = .039]) and presenting findings (lymphopenia [aOR 1.9, 95% CI 1.1–3.5, P = .033], abnormal chest imaging [aOR 2.9, 95% CI 1.1–7.5, P = .027]) were independently associated with mortality. Multiple measures of immunosuppression intensity were not associated with mortality. Conclusions: Mortality among SOT recipients hospitalized for COVID-19 was 20.5%. Age and underlying comorbidities rather than immunosuppression intensity-related measures were major drivers of mortality.

1 December 2013 in Journal of Virology
Verified
Journal Article
Open access
PDF file
Eddie A. JamesEddie A. James
Eddie A. James
RLRebecca E. LaFond
Rebecca E. LaFond
TGTheresa J. Gates
Theresa J. Gates
DMDuy T. Mai
Duy T. Mai
UMUma Malhotra
Uma Malhotra
WKWilliam W. Kwok
William W. Kwok
Yellow fever virus (YFV) can induce acute, life-threatening disease that is a significant health burden in areas where yellow fever is endemic, but it is preventable through vaccination. The live attenuated 17D YFV strain induces responses characterized by neutralizing antibodies and strong T cell responses. This vaccine provides an excellent model for studying human immunity. While several studies have characterized YFV-specific antibody and CD8 + T cell responses, less is known about YFV-specific CD4 + T cells. Here we characterize the epitope specificity, functional attributes, and dynamics of YFV-specific T cell responses in vaccinated subjects by investigating peripheral blood mononuclear cells by using HLA-DR tetramers. A total of 112 epitopes restricted by seven common HLA-DRB1 alleles were identified. Epitopes were present within all YFV proteins, but the capsid, envelope, NS2a, and NS3 proteins had the highest epitope density. Antibody blocking demonstrated that the majority of YFV-specific T cells were HLA-DR restricted. Therefore, CD4 + T cell responses could be effectively characterized with HLA-DR tetramers. Ex vivo tetramer analysis revealed that YFV-specific T cells persisted at frequencies ranging from 0 to 100 cells per million that are detectable years after vaccination. Longitudinal analysis indicated that YFV-specific CD4 + T cells reached peak frequencies, often exceeding 250 cells per million, approximately 2 weeks after vaccination. As frequencies subsequently declined, YFV-specific cells regained CCR7 expression, indicating a shift from effector to central memory. Cells were typically CXCR3 positive, suggesting Th1 polarization, and produced gamma interferon and other cytokines after reactivation in vitro . Therefore, YFV elicits robust early effector CD4 + T cell responses that contract, forming a detectable memory population.

1 January 2000 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
UMUma Malhotra
Uma Malhotra
MBM. Michelle Berrey
M. Michelle Berrey
YHYijian Huang
Yijian Huang
JMJanan Markee
Janan Markee
DBDarin J. Brown
Darin J. Brown
MMM. Juliana McElrath
M. Juliana McElrath
T-cell responses were evaluated prospectively in 41 patients with acute human immunodeficiency virus type 1 (HIV-1) infection (30 untreated and 11 re

15 February 2001 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
UMUma Malhotra
Uma Malhotra
SHSarah Holte
Sarah Holte
SDSujay Dutta
Sujay Dutta
MBM. Michelle Berrey
M. Michelle Berrey
EDElizabeth Delpit
Elizabeth Delpit
MMM. Juliana McElrath
M. Juliana McElrath
HIV-1–infected patients treated early with combination antiretrovirals respond favorably, but not all maintain viral suppression and improved HIV-specific Th function. To understand if genetic factors contribute to this variation, we prospectively evaluated over 18 months 21 early-treated patients stratified by alleles of class II haplotypes. All seven subjects with the DRB1*13-DQB1*06 haplotype, but only 21% of other subjects, maintained virus suppression at every posttreatment measurement. Following HIV-1 p24 antigen stimulation, PBMCs from patients with this haplotype demonstrated higher mean lymphoproliferation and IFN-γ secretion than did cells from patients with other haplotypes. Two DRB1*13-restricted Gag epitope regions were identified, a promiscuous one that bound its putative restriction element with nanomolar affinity, and another that mapped to a highly conserved region. These findings suggest that class II molecules, particularly the DRB1*13 haplotype, have an important impact on virologic and immunologic responses. The advantage of the haplotype may relate to selection of key HIV-1 Th1 epitopes in highly conserved regions with avid binding to class II molecules. Eliciting responses to the promiscuous epitope region may be beneficial in vaccine strategies.

1 October 2003 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JCJianhong Cao
Jianhong Cao
JMJohn McNevin
John McNevin
UMUma Malhotra
Uma Malhotra
MMM. Juliana McElrath
M. Juliana McElrath
Induction of HIV-1-specific CD8+ T cells during acute infection is associated with a decline in viremia. The role CD8+ effectors play in subsequently establishing viral set point remains unclear. To address this, we focused on two acutely infected patients with the same initial Tat-specific CD8+ response, analyzing their CD8+ T cell responses longitudinally in conjunction with viral load and sequence evolution. In one patient initiating treatment during acute infection, the frequencies of Tat-specific CD8+ T cells gradually diminished but persisted, and the Tat epitope sequence was unaltered. By contrast, in the second patient who declined treatment, the Tat-specific CD8+ T cells disappeared below detection, in conjunction with Gag-specific CD4+ T cell loss, as plasma viremia reached a set point. This coincided with the emergence of an escape variant within the Tat epitope and an additional Vpr epitope. New CD8+ T cell responses emerged but with no further associated decline in viremia. These findings indicate that, in the absence of treatment, the initial CD8+ T cell responses have the greatest impact on reducing viremia, and that later, continuously evolving responses are less efficient in further reducing viral load. The results also suggest that T cell help may contribute to the antiviral efficiency of the acute CD8+ T cell response.

1 November 2006 in Vaccine
Verified
Journal Article
Closed access
FLFusheng Li
Fusheng Li
UMUma Malhotra
Uma Malhotra
PGPeter B. Gilbert
Peter B. Gilbert
NHNatalie R. Hawkins
Natalie R. Hawkins
ADAnn C. Duerr
Ann C. Duerr
SSSteven G. Self
Steven G. Self